These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25907251)

  • 21. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
    Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Penalized variable selection for cause-specific hazard frailty models with clustered competing-risks data.
    Rakhmawati TW; Ha ID; Lee H; Lee Y
    Stat Med; 2021 Dec; 40(29):6541-6557. PubMed ID: 34541690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole genome prediction of bladder cancer risk with the Bayesian LASSO.
    de Maturana EL; Chanok SJ; Picornell AC; Rothman N; Herranz J; Calle ML; García-Closas M; Marenne G; Brand A; Tardón A; Carrato A; Silverman DT; Kogevinas M; Gianola D; Real FX; Malats N
    Genet Epidemiol; 2014 Jul; 38(5):467-76. PubMed ID: 24796258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study.
    Vetterlein MW; Gild P; Kluth LA; Seisen T; Gierth M; Fritsche HM; Burger M; Protzel C; Hakenberg OW; von Landenberg N; Roghmann F; Noldus J; Nuhn P; Pycha A; Rink M; Chun FK; May M; Fisch M; Aziz A;
    BJU Int; 2018 Jan; 121(1):101-110. PubMed ID: 28905486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coupled variable selection for regression modeling of complex treatment patterns in a clinical cancer registry.
    Schmidtmann I; Elsäßer A; Weinmann A; Binder H
    Stat Med; 2014 Dec; 33(30):5358-70. PubMed ID: 25345575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes.
    Poguntke I; Schumacher M; Beyersmann J; Wolkewitz M
    BMC Med Res Methodol; 2018 Jul; 18(1):79. PubMed ID: 30012114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the modified unbounded penalty and the LASSO to select predictive genes of response to chemotherapy in breast cancer.
    Collignon O; Han J; An H; Oh S; Lee Y
    PLoS One; 2018; 13(10):e0204897. PubMed ID: 30273405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Penalized estimation for competing risks regression with applications to high-dimensional covariates.
    Ambrogi F; Scheike TH
    Biostatistics; 2016 Oct; 17(4):708-21. PubMed ID: 27118123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allowing for mandatory covariates in boosting estimation of sparse high-dimensional survival models.
    Binder H; Schumacher M
    BMC Bioinformatics; 2008 Jan; 9():14. PubMed ID: 18186927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
    Bao Z; Zhang W; Dong D
    Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dimensional variable selection and prediction under competing risks with application to SEER-Medicare linked data.
    Hou J; Paravati A; Hou J; Xu R; Murphy J
    Stat Med; 2018 Oct; 37(24):3486-3502. PubMed ID: 29845637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.
    Cantagallo E; De Backer M; Kicinski M; Ozenne B; Collette L; Legrand C; Buyse M; Péron J
    Biom J; 2021 Feb; 63(2):272-288. PubMed ID: 32939818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of techniques for linking high-dimensional molecular data to time-to-event endpoints by risk prediction models.
    Binder H; Porzelius C; Schumacher M
    Biom J; 2011 Mar; 53(2):170-89. PubMed ID: 21328602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Semiparametric accelerated failure time cure rate mixture models with competing risks.
    Choi S; Zhu L; Huang X
    Stat Med; 2018 Jan; 37(1):48-59. PubMed ID: 28983935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSHREG: a SAS macro for proportional and nonproportional subdistribution hazards regression.
    Kohl M; Plischke M; Leffondré K; Heinze G
    Comput Methods Programs Biomed; 2015 Feb; 118(2):218-33. PubMed ID: 25572709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.
    Gu J; Zhao H; Dinney CP; Zhu Y; Leibovici D; Bermejo CE; Grossman HB; Wu X
    Clin Cancer Res; 2005 Feb; 11(4):1408-15. PubMed ID: 15746040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating and testing for center effects in competing risks.
    Katsahian S; Boudreau C
    Stat Med; 2011 Jun; 30(13):1608-17. PubMed ID: 21341296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Linear and nonlinear variable selection in competing risks data.
    Ren X; Li S; Shen C; Yu Z
    Stat Med; 2018 Jun; 37(13):2134-2147. PubMed ID: 29579776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.
    Alvarez-Múgica M; Fernández-Gómez JM; Cebrian V; Fresno F; Escaf S; Sánchez-Carbayo M
    Eur Urol; 2013 Feb; 63(2):364-70. PubMed ID: 22682992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients.
    de Glas NA; Kiderlen M; Vandenbroucke JP; de Craen AJ; Portielje JE; van de Velde CJ; Liefers GJ; Bastiaannet E; Le Cessie S
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26614095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.